Tissue Plasminogen Activator (tPA)

DRUG3 trials

Sponsors

Sir Charles Gairdner Hospital, D-Pharm Ltd., David Dornbos

Conditions

Intraventricular Brain HemorrhageIschemic StrokePeritoneal DialysisPeritoneal Dialysis, Continuous AmbulatoryTissue Plasminogen Activator

Phase 1

The Safety and Tolerability of Intra-abdominal t-PA and DNase on Peritonitis in Peritoneal Dialysis Patients

TerminatedNCT01478698

Sir Charles Gairdner HospitalPeritoneal Dialysis, Peritoneal Dialysis, Continuous Ambulatory

Start: 2016-01-01End: 2022-05-13Updated: 2022-05-19

Phase 2

A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA

D-Pharm Ltd.Ischemic Stroke

Start: 2015-10-31End: 2016-04-30Target: 40Updated: 2015-11-17

Phase 4

CleaRRAflow: Isotonic Solution vs. TPA for IVH Clearance

Not yet recruitingNCT07643493

David DornbosIntraventricular Brain Hemorrhage, Tissue Plasminogen Activator

Start: 2026-07-13End: 2029-05-31Target: 80Updated: 2026-07-08